CB
RCUS icon

Chris Bulman’s Arcus Biosciences RCUS Stock Holding History

Chris Bulman’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-464
Closed -$7.07K – 327
2024
Q2 		$7.07K Buy
+464
New +$7.49K ﹤0.01% 309

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Chris Bulman's RCUS Position: Q3 2024 in Review

Chris Bulman sold out of Arcus Biosciences (RCUS) in Q3 2024, closing a stake of 464 shares — an estimated $7.07K sold.

Chris Bulman first reported a position in RCUS in Q2 2024 and held it in 1 quarter. The position peaked at $7.07K in Q2 2024. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2024.

  • Chris Bulman reported no remaining Arcus Biosciences position as of Q3 2024 after selling out during the quarter.
  • Chris Bulman sold 464 Arcus Biosciences shares in Q3 2024, an estimated $7.07K.
  • Chris Bulman first reported a position in Arcus Biosciences in Q2 2024 and held it in 1 quarter.
  • Chris Bulman's Arcus Biosciences position peaked at $7.07K in Q2 2024.
  • 187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2024.

Based on Chris Bulman's 13F filing for Q3 2024, filed 22 Oct 2024.